Selected research
Industry Research
Glioblastoma Treatment Drugs Industry Research Report 2026
Market perspective
The global Glioblastoma Treatment Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Glioblastoma Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Glioblastoma Treatment Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Glioblastoma Treatment Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Glioblastoma Treatment Drugs include Sandoz, Merck & Co., Bristol-Myers Squibb Company, Sigma-Tau Pharmaceuticals, F. Hoffmann-La Roche AG, Emcure Pharmaceuticals Ltd. and Arbor Pharms LLC., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Glioblastoma Treatment Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Glioblastoma Treatment Drugs Market by Company
Sandoz
Merck & Co.
Bristol-Myers Squibb Company
Sigma-Tau Pharmaceuticals
F. Hoffmann-La Roche AG
Emcure Pharmaceuticals Ltd.
Arbor Pharms LLC.
Glioblastoma Treatment Drugs Segment by Type
Miscellaneous Antineoplastic
Alkylating Agents
VEGF/VEGFR Inhibitor
Glioblastoma Treatment Drugs Segment by Application
Diagnostic Centers
Long Term Care Center
Hospital
Cancer Research Organization
Glioblastoma Treatment Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glioblastoma Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glioblastoma Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glioblastoma Treatment Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Glioblastoma Treatment Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Glioblastoma Treatment Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Glioblastoma Treatment Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Miscellaneous Antineoplastic
- Alkylating Agents
- VEGF/VEGFR Inhibitor
Applications
- Diagnostic Centers
- Long Term Care Center
- Hospital
- Cancer Research Organization
Companies covered
- Sandoz
- Merck & Co.
- Bristol-Myers Squibb Company
- Sigma-Tau Pharmaceuticals
- F. Hoffmann-La Roche AG
- Emcure Pharmaceuticals Ltd.
- Arbor Pharms LLC.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Glioblastoma Treatment Drugs Market Size (2021-2032)
- 2.2.2 Global Glioblastoma Treatment Drugs Sales (2021-2032)
- 2.2.3 Global Glioblastoma Treatment Drugs Market Average Price (2021-2032)
- 2.3 Glioblastoma Treatment Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Miscellaneous Antineoplastic
- 2.3.3 Alkylating Agents
- 2.3.4 VEGF/VEGFR Inhibitor
- 2.4 Glioblastoma Treatment Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Diagnostic Centers
- 2.4.3 Long Term Care Center
- 2.4.4 Hospital
- 2.4.5 Cancer Research Organization
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Glioblastoma Treatment Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Glioblastoma Treatment Drugs Sales (tons) of Manufacturers (2021-2026)
- 3.3 Global Glioblastoma Treatment Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Glioblastoma Treatment Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Glioblastoma Treatment Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Glioblastoma Treatment Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Glioblastoma Treatment Drugs, Product Type & Application
- 3.8 Global Manufacturers of Glioblastoma Treatment Drugs, Established Date
- 3.9 Global Glioblastoma Treatment Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sandoz
- 4.1.1 Sandoz Company Information
- 4.1.2 Sandoz Business Overview
- 4.1.3 Sandoz Glioblastoma Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sandoz Glioblastoma Treatment Drugs Product Portfolio
- 4.1.5 Sandoz Recent Developments
- 4.2 Merck & Co.
- 4.2.1 Merck & Co. Company Information
- 4.2.2 Merck & Co. Business Overview
- 4.2.3 Merck & Co. Glioblastoma Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co. Glioblastoma Treatment Drugs Product Portfolio
- 4.2.5 Merck & Co. Recent Developments
- 4.3 Bristol-Myers Squibb Company
- 4.3.1 Bristol-Myers Squibb Company Company Information
- 4.3.2 Bristol-Myers Squibb Company Business Overview
- 4.3.3 Bristol-Myers Squibb Company Glioblastoma Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bristol-Myers Squibb Company Glioblastoma Treatment Drugs Product Portfolio
- 4.3.5 Bristol-Myers Squibb Company Recent Developments
- 4.4 Sigma-Tau Pharmaceuticals
- 4.4.1 Sigma-Tau Pharmaceuticals Company Information
- 4.4.2 Sigma-Tau Pharmaceuticals Business Overview
- 4.4.3 Sigma-Tau Pharmaceuticals Glioblastoma Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sigma-Tau Pharmaceuticals Glioblastoma Treatment Drugs Product Portfolio
- 4.4.5 Sigma-Tau Pharmaceuticals Recent Developments
- 4.5 F. Hoffmann-La Roche AG
- 4.5.1 F. Hoffmann-La Roche AG Company Information
- 4.5.2 F. Hoffmann-La Roche AG Business Overview
- 4.5.3 F. Hoffmann-La Roche AG Glioblastoma Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 F. Hoffmann-La Roche AG Glioblastoma Treatment Drugs Product Portfolio
- 4.5.5 F. Hoffmann-La Roche AG Recent Developments
- 4.6 Emcure Pharmaceuticals Ltd.
- 4.6.1 Emcure Pharmaceuticals Ltd. Company Information
- 4.6.2 Emcure Pharmaceuticals Ltd. Business Overview
- 4.6.3 Emcure Pharmaceuticals Ltd. Glioblastoma Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Emcure Pharmaceuticals Ltd. Glioblastoma Treatment Drugs Product Portfolio
- 4.6.5 Emcure Pharmaceuticals Ltd. Recent Developments
- 4.7 Arbor Pharms LLC.
- 4.7.1 Arbor Pharms LLC. Company Information
- 4.7.2 Arbor Pharms LLC. Business Overview
- 4.7.3 Arbor Pharms LLC. Glioblastoma Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Arbor Pharms LLC. Glioblastoma Treatment Drugs Product Portfolio
- 4.7.5 Arbor Pharms LLC. Recent Developments
5 Global Glioblastoma Treatment Drugs Market Scenario by Region
- 5.1 Global Glioblastoma Treatment Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Glioblastoma Treatment Drugs Sales by Region: 2021-2032
- 5.2.1 Global Glioblastoma Treatment Drugs Sales by Region: 2021-2026
- 5.2.2 Global Glioblastoma Treatment Drugs Sales by Region: 2027-2032
- 5.3 Global Glioblastoma Treatment Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Glioblastoma Treatment Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Glioblastoma Treatment Drugs Revenue by Region: 2027-2032
- 5.4 North America Glioblastoma Treatment Drugs Market Facts & Figures by Country
- 5.4.1 North America Glioblastoma Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Glioblastoma Treatment Drugs Sales by Country (2021-2032)
- 5.4.3 North America Glioblastoma Treatment Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Glioblastoma Treatment Drugs Market Facts & Figures by Country
- 5.5.1 Europe Glioblastoma Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Glioblastoma Treatment Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Glioblastoma Treatment Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Glioblastoma Treatment Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Glioblastoma Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Glioblastoma Treatment Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Glioblastoma Treatment Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Glioblastoma Treatment Drugs Market Facts & Figures by Country
- 5.7.1 South America Glioblastoma Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Glioblastoma Treatment Drugs Sales by Country (2021-2032)
- 5.7.3 South America Glioblastoma Treatment Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Glioblastoma Treatment Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Glioblastoma Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Glioblastoma Treatment Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Glioblastoma Treatment Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Glioblastoma Treatment Drugs Sales by Type (2021-2032)
- 6.1.1 Global Glioblastoma Treatment Drugs Sales by Type (2021-2032) & (tons)
- 6.1.2 Global Glioblastoma Treatment Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Glioblastoma Treatment Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Glioblastoma Treatment Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Glioblastoma Treatment Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Glioblastoma Treatment Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Glioblastoma Treatment Drugs Sales by Application (2021-2032)
- 7.1.1 Global Glioblastoma Treatment Drugs Sales by Application (2021-2032) & (tons)
- 7.1.2 Global Glioblastoma Treatment Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Glioblastoma Treatment Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Glioblastoma Treatment Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Glioblastoma Treatment Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Glioblastoma Treatment Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Glioblastoma Treatment Drugs Value Chain Analysis
- 8.1.1 Glioblastoma Treatment Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Glioblastoma Treatment Drugs Production Mode & Process
- 8.2 Glioblastoma Treatment Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Glioblastoma Treatment Drugs Distributors
- 8.2.3 Glioblastoma Treatment Drugs Customers
9 Global Glioblastoma Treatment Drugs Analyzing Market Dynamics
- 9.1 Glioblastoma Treatment Drugs Industry Trends
- 9.2 Glioblastoma Treatment Drugs Industry Drivers
- 9.3 Glioblastoma Treatment Drugs Industry Opportunities and Challenges
- 9.4 Glioblastoma Treatment Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst